Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EPHX2 | P34913 | 1/20 | 0.65 |
| ▸ | FAAH | O00519 | 3/20 | 0.53 |
| ▸ | NAMPT | P43490 | 1/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.51 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.51 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.50 |
| ▸ | PRKAB2 | O43741 | 4/20 | 0.49 |
| ▸ | PRKAG1 | P54619 | 4/20 | 0.49 |
| ▸ | PRKAA2 | P54646 | 4/20 | 0.49 |
| ▸ | PRKAA1 | Q13131 | 4/20 | 0.49 |
| ▸ | PRKAG3 | Q9UGI9 | 4/20 | 0.49 |
| ▸ | PRKAG2 | Q9UGJ0 | 4/20 | 0.49 |
| ▸ | PRKAB1 | Q9Y478 | 4/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.49 |
| ▸ | CA1 | P00915 | 1/20 | 0.49 |
| ▸ | CA2 | P00918 | 1/20 | 0.49 |
| ▸ | GPR183 | P32249 | 1/20 | 0.48 |
| ▸ | LMNA | P02545 | 1/20 | 0.48 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5652115 | 0.84 | EPHX2 (0.57) | EPHX2NAMPTPOLBALDH1A1KDM4E | |
| SCHEMBL5649851 | 0.83 | HIF1A (0.49) | EPHX2FAAHNAMPTALDH1A1KDM4E | |
| SCHEMBL5649701 | 0.83 | EPHX2 (0.64) | EPHX2NAMPTPOLBALDH1A1KDM4E | |
| SCHEMBL12931990 | 0.81 | EPHX2 (1.00) | EPHX2NAMPTALDH1A1KMT2AGPR183 | |
| SCHEMBL5648227 | 0.79 | EPHX2 (0.59) | EPHX2NAMPTPOLBALDH1A1KDM4E | |
| SCHEMBL5649096 | 0.79 | KMT2A (0.64) | EPHX2NAMPTALDH1A1KDM4EKMT2A | |
| SCHEMBL5648192 | 0.74 | EPHX2 (0.71) | EPHX2NAMPTPOLBALDH1A1KDM4E | |
| SCHEMBL13930859 | 0.73 | ALDH1A1 (0.66) | EPHX2NAMPTALDH1A1KMT2ACA1 | |
| SCHEMBL23747572 | 0.72 | SMN1; SMN2 (0.61) | FAAHPOLBALDH1A1KDM4EPRKAB2 | |
| SCHEMBL12655873 | 0.71 | FAAH (0.80) | FAAHPOLBALDH1A1PRKAB2PRKAG1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| JP-2006527212-A | — | — | 2006-11-30 | — | — | JP | claimed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | claimed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | claimed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | claimed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | claimed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | claimed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | claimed |
| US-7279470-B2 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2007-10-09 | — | — | US | disclosed |
| US-20060160820-A1 | Substituted piperazine carbamates | NOVO NORDISK A/S (DK) | 2006-07-20 | — | — | US | disclosed |
| US-7067517-B2 | Use of compounds for decreasing activity of hormone-sensitive lipase | NERO NORDISK A/S (DK) | 2006-06-27 | — | — | US | disclosed |
| EP-1636187-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2006-03-22 | — | — | EP | disclosed |
| WO-2004111004-A1 | SUBSTITUTED PIPERAZINE CARBAMATES FOR USE AS INHIBITORS OF HORMONE SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-12-23 | — | — | WO | disclosed |
| EP-1458375-A2 | COMPOSITIONS FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| EP-1458374-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2004-09-22 | — | — | EP | disclosed |
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | NOVO NORDISK A/S (DK) | 2003-09-04 | — | — | US | disclosed |
| WO-2003051842-A2 | COMPOSITIONS DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
| WO-2003051841-A2 | COMPOUNDS AND USES THEREOF FOR DECREASING ACTIVITY OF HORMONE-SENSITIVE LIPASE | NOVO NORDISK A/S (DK) | 2003-06-26 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030166644-A1 | Compounds and uses thereof for decreasing activity of hormone-sensitive lipase | LIPE, PNLIP, LPL | EPHX2 1180/4885FAAH 474/4885NAMPT 1236/4885 |
| US-20030166690-A1 | Use of compounds for decreasing activity of hormone-sensitive | LIPE, PNLIP, LPL | EPHX2 1667/4885FAAH 352/4885NAMPT 1483/4885 |
| US-20060160820-A1 | Substituted piperazine carbamates | LIPE, PNLIP, LPL | EPHX2 2683/4885FAAH 219/4885NAMPT 2884/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.